JP2022551316A - Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 - Google Patents

Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 Download PDF

Info

Publication number
JP2022551316A
JP2022551316A JP2022521569A JP2022521569A JP2022551316A JP 2022551316 A JP2022551316 A JP 2022551316A JP 2022521569 A JP2022521569 A JP 2022521569A JP 2022521569 A JP2022521569 A JP 2022521569A JP 2022551316 A JP2022551316 A JP 2022551316A
Authority
JP
Japan
Prior art keywords
compound
theta
disorder
present disclosure
disclosure provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022521569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551316A5 (https=
JPWO2021069711A5 (https=
Inventor
トマス ブランドル、マイケル
アンドレス、パトリシア
アイ． ヴラホヴァ、ペティンカ
智彦 坂口
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2022551316A publication Critical patent/JP2022551316A/ja
Publication of JP2022551316A5 publication Critical patent/JP2022551316A5/ja
Publication of JPWO2021069711A5 publication Critical patent/JPWO2021069711A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2022521569A 2019-10-10 2020-10-09 Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 Pending JP2022551316A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913560P 2019-10-10 2019-10-10
US62/913,560 2019-10-10
PCT/EP2020/078493 WO2021069711A1 (en) 2019-10-10 2020-10-09 Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea

Publications (3)

Publication Number Publication Date
JP2022551316A true JP2022551316A (ja) 2022-12-08
JP2022551316A5 JP2022551316A5 (https=) 2023-10-17
JPWO2021069711A5 JPWO2021069711A5 (https=) 2023-10-17

Family

ID=72852650

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022521569A Pending JP2022551316A (ja) 2019-10-10 2020-10-09 Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形

Country Status (5)

Country Link
US (2) US12338249B2 (https=)
EP (1) EP4041739A1 (https=)
JP (1) JP2022551316A (https=)
CN (1) CN115279769A (https=)
WO (1) WO2021069711A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2912929T5 (en) 2016-09-30 2025-05-09 Sumitomo Pharma Switzerland Gmbh Methods of treating uterine fibroids and endometriosis
US12441738B2 (en) 2018-03-14 2025-10-14 Assia Chemical Industries Ltd. Solid state forms of Relugolix
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
CA3185151A1 (en) 2020-05-29 2021-12-02 Myovant Sciences Gmbh Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
CN113620972A (zh) * 2021-02-02 2021-11-09 奥锐特药业(天津)有限公司 瑞卢戈利新晶型及其制备方法
WO2022214645A1 (en) 2021-04-09 2022-10-13 Farmhispania Group, S.L. Processes and intermediates for the preparation of relugolix
JP2024540922A (ja) 2021-10-18 2024-11-06 スミトモ ファーマ スウィッツァーランド ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素のエタノール溶媒和物の結晶形

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010229098A (ja) * 2009-03-27 2010-10-14 Central Glass Co Ltd イソインドリン誘導体のａ型の結晶形の製造方法及びイソインドリン誘導体のａ型の結晶形
JP2015532262A (ja) * 2012-09-28 2015-11-09 武田薬品工業株式会社 チエノピリミジン誘導体の製造方法
JP2017088564A (ja) * 2015-11-13 2017-05-25 株式会社トクヤマ ミルタザピンの製造方法
WO2018060463A2 (en) * 2016-09-30 2018-04-05 Myovant Sciences Gmbh Treatment of prostate cancer
JP2018538348A (ja) * 2015-12-25 2018-12-27 シュアンチュー ファーマ カンパニー，リミティド キナゾリン誘導体の結晶及びその調製方法
JP2019038825A (ja) * 2013-11-01 2019-03-14 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態及びその使用
JP2019511510A (ja) * 2016-03-28 2019-04-25 ウォーソー・オーソペディック・インコーポレーテッド オキシステロールの多型およびそれらの製造方法
WO2019178304A1 (en) * 2018-03-14 2019-09-19 Teva Pharmaceuticals International Gmbh Solid state forms of relugolix

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5116436B1 (https=) 1971-05-31 1976-05-24
EP0237289A3 (en) 1986-03-14 1988-07-27 Takeda Chemical Industries, Ltd. Pyrazolo [3,4-d] pyrimidine derivatives, their production and use
JP2859791B2 (ja) 1992-01-31 1999-02-24 吉富製薬株式会社 ４−ブロモメチルビフェニル化合物の製造法
US5312958A (en) 1992-01-31 1994-05-17 Takeda Chemical Industries, Ltd. Process for producing 4-bromomethylbiphenyl compounds
JPH10298156A (ja) 1997-04-28 1998-11-10 Nippon Nohyaku Co Ltd 置換ハロメチルフェニルカルバミド酸エステル類の製造方法
US6297379B1 (en) 1999-03-24 2001-10-02 Takeda Chemical Industries, Ltd. Thienopyrimidine compounds, their production and use
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
JP2001316391A (ja) 2000-02-29 2001-11-13 Takeda Chem Ind Ltd チエノピリミジン誘導体の製造法
US6849738B2 (en) 2000-02-29 2005-02-01 Takeda Chemical Industries, Ltd. Processes for the production of thienopyrimidine derivatives
GB2361917A (en) 2000-05-04 2001-11-07 Astrazeneca Ab Novel thieno[2,3-d]pyrimidinediones
JP2002088044A (ja) 2000-09-14 2002-03-27 Sumitomo Seika Chem Co Ltd ４’−ブロモメチル−２−シアノビフェニルの製造方法
HUP0401443A3 (en) 2001-09-04 2008-05-28 Organon Nv Glycine-substituted thieno[2,3-d]pyrimidines with lh and fsh agonistic activity, use of the compounds and pharmaceutical compositions containing same
WO2003064429A1 (en) 2002-01-30 2003-08-07 Takeda Chemical Industries, Ltd. Thienopyrimidines, process for preparing the same and use thereof
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
US7300935B2 (en) 2003-01-29 2007-11-27 Takeda Pharmaceutical Company Thienopyrimidine compounds and use thereof
WO2006014647A2 (en) 2004-07-21 2006-02-09 Athersys, Inc. Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
WO2006046485A1 (ja) 2004-10-25 2006-05-04 Nihon Nohyaku Co., Ltd. 畑作用除草剤組成物及び防除方法
ES2494842T3 (es) 2005-07-22 2014-09-16 Takeda Pharmaceutical Company Limited Agente que previene la ovulación precoz
WO2010026993A1 (ja) 2008-09-03 2010-03-11 武田薬品工業株式会社 製剤における吸収性改善方法および吸収性が改善された製剤
TWI508962B (zh) 2009-04-22 2015-11-21 Du Pont 氮雜環醯胺之固體形態
TWI744224B (zh) 2015-02-26 2021-11-01 日商武田藥品工業股份有限公司 固形製劑
TWI726969B (zh) * 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
ES2912929T5 (en) 2016-09-30 2025-05-09 Sumitomo Pharma Switzerland Gmbh Methods of treating uterine fibroids and endometriosis
US12441738B2 (en) 2018-03-14 2025-10-14 Assia Chemical Industries Ltd. Solid state forms of Relugolix
EP3666776A1 (en) * 2018-12-11 2020-06-17 Sandoz AG Hydrate of a gonadotropin-releasing hormone receptor antagonist
US20220220123A1 (en) * 2019-05-15 2022-07-14 Dr. Reddy's Laboratories Limited Amorphous and crystalline forms of relugolix
CN114174302A (zh) * 2019-08-02 2022-03-11 庄信万丰股份有限公司 瑞卢戈利的固态形式
CN112390812A (zh) * 2019-08-14 2021-02-23 苏州鹏旭医药科技有限公司 瑞卢戈利化合物的晶型和无定型固体及其制备方法
WO2021031148A1 (zh) 2019-08-21 2021-02-25 深圳仁泰医药科技有限公司 促性腺素释放激素拮抗剂的晶型及其制备方法和用途
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
WO2021069700A1 (en) 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN111423452B (zh) * 2020-03-26 2023-08-22 江西青峰药业有限公司 瑞卢戈利的中间体及其制备方法和应用
CN111333633B (zh) * 2020-04-01 2023-10-20 江西科睿药业有限公司 一种瑞卢戈利的中间体化合物及其制备方法和用途
CA3185151A1 (en) 2020-05-29 2021-12-02 Myovant Sciences Gmbh Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
US11655256B1 (en) 2020-11-06 2023-05-23 Macfarlan Smith Limited Processes for making a solid-state form of relugolix
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
CN112552312B (zh) 2020-12-07 2022-08-05 杭州科巢生物科技有限公司 一种瑞卢戈利或其盐的合成方法
CN113620972A (zh) 2021-02-02 2021-11-09 奥锐特药业(天津)有限公司 瑞卢戈利新晶型及其制备方法
US20240287090A1 (en) 2021-09-15 2024-08-29 Cipla Limited Solid state forms of relugolix
CN115947734A (zh) 2021-10-09 2023-04-11 江苏希迪制药有限公司 瑞卢戈利溶剂化物的晶型及其制备方法
JP2024540922A (ja) 2021-10-18 2024-11-06 スミトモ ファーマ スウィッツァーランド ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素のエタノール溶媒和物の結晶形
WO2023119333A1 (en) 2021-12-25 2023-06-29 Dr. Reddy’S Laboratories Limited Process for preparation of relugolix and its intermediates
IN202221021078A (https=) 2022-04-08 2023-10-13
CN115417883B (zh) 2022-09-16 2024-08-27 浙江科聚生物医药有限公司 一种瑞卢戈利的晶型及其制备方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010229098A (ja) * 2009-03-27 2010-10-14 Central Glass Co Ltd イソインドリン誘導体のａ型の結晶形の製造方法及びイソインドリン誘導体のａ型の結晶形
JP2015532262A (ja) * 2012-09-28 2015-11-09 武田薬品工業株式会社 チエノピリミジン誘導体の製造方法
JP2019038825A (ja) * 2013-11-01 2019-03-14 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態及びその使用
JP2017088564A (ja) * 2015-11-13 2017-05-25 株式会社トクヤマ ミルタザピンの製造方法
JP2018538348A (ja) * 2015-12-25 2018-12-27 シュアンチュー ファーマ カンパニー，リミティド キナゾリン誘導体の結晶及びその調製方法
JP2019511510A (ja) * 2016-03-28 2019-04-25 ウォーソー・オーソペディック・インコーポレーテッド オキシステロールの多型およびそれらの製造方法
WO2018060463A2 (en) * 2016-09-30 2018-04-05 Myovant Sciences Gmbh Treatment of prostate cancer
WO2019178304A1 (en) * 2018-03-14 2019-09-19 Teva Pharmaceuticals International Gmbh Solid state forms of relugolix

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0005432693 *
芦澤 一英: "塩・結晶形の最適化と結晶化技術", PHARM TECH JAPAN, vol. 18, no. 10, JPN6013060608, 2002, pages 81 - 96, ISSN: 0005432694 *

Also Published As

Publication number Publication date
EP4041739A1 (en) 2022-08-17
WO2021069711A1 (en) 2021-04-15
CN115279769A (zh) 2022-11-01
US20260042775A1 (en) 2026-02-12
US20220396582A1 (en) 2022-12-15
US12338249B2 (en) 2025-06-24

Similar Documents

Publication Publication Date Title
US20260042775A1 (en) Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
TWI870922B (zh) 作為sos1抑制劑之新穎芐胺基取代吡啶并嘧啶酮及衍生物
US20220372044A1 (en) Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
KR102785137B1 (ko) Rip1 억제 화합물 및 그를 제조 및 사용하는 방법
JP7379641B2 (ja) Ｉｒａｋ阻害剤としてのピラゾールアミド化合物
CN111712484B (zh) 作为免疫调节的芳环衍生物及其制备方法和应用
EP3390390B1 (en) Bipyrazolyl derivatives useful for the treatment of autoimmune diseases
JP2019533687A5 (https=)
WO2016192132A1 (zh) 作为alk抑制剂的嘧啶衍生物
JP2019510025A (ja) ピリミジンおよびそのバリアント、ならびにそのための使用
ES2561298T3 (es) Compuestos de aminometilquinolona
WO2024141128A4 (zh) Sting抑制剂前药及其医药用途
TW202228684A (zh) 新型苯并氮雜卓螺環衍生物
WO2023284807A1 (zh) 含四氢萘啶酮或四氢吡啶并嘧啶酮骨架的化合物及其制备方法与制药用途
CN113135970A (zh) 一种具有抗芽孢活性的化合物及其药用组合物
CN111630029B (zh) 作为免疫调节剂的化合物及其制备方法和应用
CN114644635B (zh) 三氮唑类三并环衍生物及其制备方法和应用
CN115650974B (zh) N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-顺式戊二烯酰胺衍生物及应用
WO2022192533A1 (en) Heterocyclic rip1 kinase inhibitors
CN1359376A (zh) 新的具有芳香基取代的氮杂环的羧酸衍生物、其制备和作为内皮素受体拮抗剂的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250401